Company profile PRLD

Prelude Therapeutics Inc
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established ther...apies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware. Show More
Quarter analysis & expected interest

There is not enough data for Prelude Therapeutics -stock to provide analysis

Correlation between past revenue and Prelude Therapeutics -stock search interest

There is not enough data for Prelude Therapeutics -stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Prelude Therapeutics -stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Prelude Therapeutics login to provide analysis

Correlation between past revenue and Prelude Therapeutics login search interest

There is not enough data for Prelude Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Prelude Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Prelude Therapeutics stock price to provide analysis

Correlation between past revenue and Prelude Therapeutics stock price search interest

There is not enough data for Prelude Therapeutics stock price to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Prelude Therapeutics stock price to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 23:30:58.

After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0.
Prelude Therapeutics IPO expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201933
117
254.5% QoQ
113
-3.4% QoQ
159
40.7% QoQ
2020 82
148.5% YoY -48.4% QoQ
81
-30.8% YoY -1.2% QoQ
48
-57.5% YoY -40.7% QoQ
93
-41.5% YoY 93.8% QoQ
2021 89
8.5% YoY -4.3% QoQ
210
159.3% YoY 136.0% QoQ
45
-6.2% YoY -78.6% QoQ
28
-69.9% YoY -37.8% QoQ
2022 190
113.5% YoY 578.6% QoQ
109
-48.1% YoY -42.6% QoQ
153
240.0% YoY 40.4% QoQ
22
-21.4% YoY -85.6% QoQ
2023 24
-87.4% YoY 9.1% QoQ
30
-72.5% YoY 25.0% QoQ
120
-21.6% YoY 300.0% QoQ
114
418.2% YoY -5.0% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Prelude Therapeutics IPO search interestLast update: February 07 2024 23:30:57.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 23:30:58.

The average 5 years interest of Prelude Therapeutics IPO was 7.15 per week.
The last year interest of Prelude Therapeutics IPO compared to the last 5 years has changed by -22.52%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -31.77%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 23:31:02.

After 38 days of this quarter the interest is at 48.0. Based on that we can calculate that during remaining 53 days it will total up to 115.0.
Prelude Therapeutics news expected interest is significantly lower compared to same quarter last year (-42.8%) but similar to previous quarter.

YearQ1Q2Q3Q4
201945
140
211.1% QoQ
149
6.4% QoQ
201
34.9% QoQ
2020 59
31.1% YoY -70.6% QoQ
134
-4.3% YoY 127.1% QoQ
0
-100.0% YoY -100.0% QoQ
83
-58.7% YoY inf% QoQ
2021 49
-16.9% YoY -41.0% QoQ
185
38.1% YoY 277.6% QoQ
36
inf% YoY -80.5% QoQ
65
-21.7% YoY 80.6% QoQ
2022 150
206.1% YoY 130.8% QoQ
49
-73.5% YoY -67.3% QoQ
128
255.6% YoY 161.2% QoQ
138
112.3% YoY 7.8% QoQ
2023 201
34.0% YoY 45.7% QoQ
94
91.8% YoY -53.2% QoQ
152
18.8% YoY 61.7% QoQ
142
2.9% YoY -6.6% QoQ
2024 48
-76.1% YoY -66.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Prelude Therapeutics news search interestLast update: February 07 2024 23:31:01.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 23:31:02.

The average 5 years interest of Prelude Therapeutics news was 8.65 per week.
The last year interest of Prelude Therapeutics news compared to the last 5 years has changed by 26.47%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 0.83%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Prelude Therapeutics pipeline to provide analysis

Correlation between past revenue and Prelude Therapeutics pipeline search interest

There is not enough data for Prelude Therapeutics pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Prelude Therapeutics pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Prelude Therapeutics clinical trials to provide analysis

Correlation between past revenue and Prelude Therapeutics clinical trials search interest

There is not enough data for Prelude Therapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Prelude Therapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for PRT811 to provide analysis

Correlation between past revenue and PRT811 search interest

There is not enough data for PRT811 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for PRT811 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for PRT1419 to provide analysis

Correlation between past revenue and PRT1419 search interest

There is not enough data for PRT1419 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for PRT1419 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for PRT2527 to provide analysis

Correlation between past revenue and PRT2527 search interest

There is not enough data for PRT2527 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for PRT2527 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PRLD
Earnings date: 2024-03-13 After close
Company name: Prelude Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T11:01:00Z

GlobeNewswire
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-04T13:58:27Z

Analyst Upgrades
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

2026-04-27T11:57:53Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

2026-04-20T10:30:00Z

GlobeNewswire
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

2026-04-20T10:00:00Z

GlobeNewswire
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-15T11:30:00Z

GlobeNewswire
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

2026-03-11T11:38:02Z

Analyst Upgrades
Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

2026-03-10T11:01:00Z

GlobeNewswire
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

2026-02-05T14:26:03Z

GlobeNewswire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

2026-02-03T14:00:00Z

GlobeNewswire
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

2025-12-16T17:18:00Z

GlobeNewswire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

2025-12-06T16:00:00Z

GlobeNewswire
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

2025-11-20T10:00:00-05:00

PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

2025-11-19T14:45:00Z

GlobeNewswire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

2025-11-12T12:01:00Z

GlobeNewswire
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update